Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ibalizumab - TaiMed Biologics

Next Previous
Drug Profile

Ibalizumab - TaiMed Biologics

Alternative Names: Hu1A8; Hu5A8; Ibalizumab-uiyk; TMB-355; TNX-355; Trogarzo

Latest Information Update: 14 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biogen Idec
  • Developer TaiMed Biologics; Theratechnologies
  • Class Antiretrovirals; Monoclonal antibodies
  • Mechanism of Action HIV fusion inhibitors; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed HIV-1 infections
  • No development reported HIV-2 infections

Most Recent Events

  • 08 Jul 2026 TaiMed Biologics receives license collection notice from the Taiwan Food and Drug Administration (TFDA) for Ibalizumab in HIV-1 infections
  • 08 Jul 2026 TaiMed Biologics plans to launch Ibalizumab in Taiwan for for HIV-1 infections
  • 30 Jun 2026 Registered for HIV-1 infections (Treatment-experienced) in Taiwan (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top